Table 5.
Treatment-Related Adverse Events in Two Groups
| Adverse Events | TACE-L-P (n = 64) | TACE-L (n = 58) | P | ||
|---|---|---|---|---|---|
| Any Grade | Grade 3–4 | Any Grade | Grade 3–4 | ||
| Diarrhea | 8 (12.5%) | 1 (1.6%) | 5 (8.6%) | 1 (1.7%) | 0.756 |
| Hand-foot syndrome | 11 (17.2%) | 4 (6.3%) | 7 (12.1%) | 2 (3.4%) | 0.808 |
| Hypertension | 17 (26.6%) | 3 (4.7%) | 13 (22.4%) | 3 (5.2%) | 0.764 |
| Fatigue | 23 (35.9%) | 3 (4.7%) | 19 (32.8%) | 2 (3.4%) | 0.824 |
| Anorexia and nausea | 25 (39.1%) | 2 (3.2%) | 21 (36.2%) | 1 (1.7%) | 0.678 |
| Rash | 19 (29.7%) | 1 (1.6%) | 20 (34.5%) | 1 (1.7%) | 0.972 |
| Oral ulcer | 15 (20.3%) | 2 (3.1%) | 13 (22.4%) | 0 (0.0%) | 0.492 |
| Thyroid dysfunction | 10 (15.6%) | 4 (6.3%) | 11 (19.0%) | 2 (3.4%) | 0.410 |
| Hyperbilirubinemia | 12 (18.8%) | 3 (4.7%) | 11 (19.0%) | 3 (5.2%) | 0.942 |
| Thrombocytopenia | 10 (15.6%) | 2 (3.1%) | 7 (12.1%) | 1 (1.7%) | 0.798 |
Note: Data were presented as n (%) or mean ± standard deviation.
Abbreviations: TACE-L-P, transarterial chemoembolization combined with lenvatinib and PD-(L)1 inhibitor; TACE-L, transarterial chemoembolization combined with lenvatinib.